Skip to main content

#Mpox Multi-country external #situation #report no. 59 published 30 October 2025 (#WHO, summary)

Image
By G.M.

 


Highlights   

• This Situation report will now be published monthly. 

• All clades of the monkeypox virus (MPXV) continue to circulate. When mpox outbreaks are not rapidly contained and human-to-human transmission is not interrupted, there is a risk of sustained community transmission.  

• In September 2025, 42 countries, across all WHO regions, reported a total of 3135 confirmed cases, including 12 deaths (case fatality ratio [CFR] 0.4%). More than 80% of these cases were reported in the African Region. Four regions (African Region, Eastern Mediterranean Region, Region of the Americas, and the Western Pacific) observed a declining trend in confirmed cases reported per month, while the European and South-East Asian regions observed an increase in cases in September 2025.

• Seventeen countries in Africa have experienced ongoing active transmission of mpox in the last six weeks (14 Sep – 19 Oct 2025), with 2862 confirmed cases, including 17 deaths (CFR 0.6%) reported during this period. Countries reporting the highest number of cases in this period are the Democratic Republic of the Congo, Liberia, Kenya and Ghana; with upward trends in Kenya and Liberia, sustained declining trends in the Democratic Republic of the Congo, and very early indications of a downward trend in Ghana. 

• Since the last edition of this report, Malaysia, Namibia, the Netherlands, Portugal, and Spain have reported detection of clade Ib monkeypox virus (MPXV) for the first time.   

• New imported cases of mpox due to clade Ib MPXV detected among travellers have been reported in Belgium, Canada, Germany, Italy, Qatar and Spain. 

• Six countries outside Central and East Africa have reported clade Ib MPXV cases among individuals without travel links, indicating local circulation of the virus in Italy, Malaysia, the Netherlands, Portugal, Spain and the United States of America. In addition to countries in Africa, these countries are now also classified as experiencing community transmission of clade Ib MPXV.  

• Since the last report, at least five cases of mpox due to clade Ib MPXV have been detected among individuals who self-identify as men who have sex with men. These cases provide the first evidence of previously undetected circulation, of this virus strain within this at-risk population, in which only clade IIb MPXV had been reported since 2022, and across different regions.  

• In light of expanding community transmission of clade Ib MPXV and its detection among men who have sex with men, WHO currently assesses the public health risk as moderate for men who have sex with men and low for the general population in contexts outside historically endemic areas. 

(...)

Source: World Health Organization, https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--59---30-october-2025

____

Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »